Impact of chemo type before CAR T-cell therapy for lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at how the type of chemotherapy given before CAR T-cell treatment affects how well the CAR T-cells work in people with aggressive large B-cell lymphoma that has come back or not responded to treatment. It aims to find out which pre-treatment approach leads to better outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have received one of the following CAR T-cell treatments: Lisocabtagene maraleucel, Tisagenlecleucel, or Axicabtagene ciloleucel
- You received the standard chemotherapy drugs Fludarabine and Cyclophosphamide before your CAR T-cell infusion
- You have an aggressive large B-cell lymphoma that came back or did not respond to at least one prior treatment
- Your kidney function (a test called creatinine clearance) is above 50 ml/min
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if giving radiation to all visible tumor sites before standard CAR T-cell therapy can improve outcomes for people with high-risk large B-cell lymphoma. You may be eligible if you have at least one large tumor (5 cm or bigger) that can be targeted with radiation.
This study looks at factors that predict how well CAR-T therapy works for large B-cell lymphoma that has come back or not responded to treatment. It aims to help doctors better identify who may benefit from this therapy.
This Phase 1/2 study tests a lab-made immune cell treatment (CAR T cells) made from your own blood cells to treat aggressive large B-cell lymphoma that has come back or didn’t respond. If you qualify, the goal is to see whether this treatment is safe and can shrink lymphoma.
This Phase 2 study looks at giving CAR-T cell therapy first, then follow-up “bispecific” antibody medicines to help keep large B-cell lymphoma from coming back. It’s for people whose lymphoma returned or did not respond to prior standard treatments and who still have measurable disease on scans.
This early-phase study tests whether giving targeted radiation first can improve outcomes when you later receive CAR T-cell therapy for large B-cell lymphoma that has come back or is not responding to treatment. It may help shrink or control lymphoma spots before CAR T is infused.
This Phase 2 study tests whether adding or switching drug treatments after CAR T-cell therapy can improve outcomes for people with certain aggressive lymphomas that have come back or did not respond. It mainly looks at who remains disease-stable/partly improved after CAR T and what treatment approach works best next.
Hear when a new Large B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.